Open Access Highly Accessed Open Badges Meeting report

FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011”

Paolo A Ascierto121*, Antonio M Grimaldi1, Brendan Curti2, Mark B Faries3, Soldano Ferrone4, Keith Flaherty5, Bernard A Fox6, Thomas F Gajewski7, Jeffrey E Gershenwald8, Helen Gogas9, Kenneth Grossmann10, Axel Hauschild11, F Stephen Hodi12, Richard Kefford13, John M Kirkwood14, Sancy Leachmann10, Michele Maio15, Richard Marais16, Giuseppe Palmieri17, Donald L Morton3, Antoni Ribas18, David F Stroncek19, Rodney Stewart10, Ena Wang20, Nicola Mozzillo1 and Franco M Marincola20

Author Affiliations

1 Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy

2 Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, USA

3 Department of Melanoma Research, John Wayne Cancer Institute at Saint John’s Health Center, Santa Monica, CA, USA

4 University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA

5 Massachusetts General Hospital Cancer Center, Boston, MA, USA

6 Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, and Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, USA

7 University of Chicago, Chicago, IL, USA

8 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

9 First Department of Medicine, Athens Medical School, University of Athens, Athens, Greece

10 Huntsman Cancer Institute, University of Utah, Melanoma and Cutaneous Oncology Program, Salt Lake City, UT, USA

11 Department of Dermatology, University of Kiel, Kiel, Germany

12 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

13 Westmead Institute for Cancer Research, Westmead Millennium Institute and Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia

14 Division of Hematology/Oncology, Departments of Medicine, Dermatology, and Translational Science, University of Pittsburgh School of Medicine and Melanoma Program of the Pittsburgh Cancer Institute, Pittsburgh, PA, USA

15 Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy

16 Molecular Oncology Group, The Paterson Institute for Cancer Research, Wilmslow Road, Manchester, M20 4BX, UK

17 Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council (CNR), Sassari, Italy

18 UCLA Medical Center, Factor Bldg., 10833 Le Conte Ave., Los Angeles, CA, 11-934, USA

19 Cell Processing Section, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, MD, USA

20 Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center and Center for Human Immunology (CHI), NIH, Bethesda, MD, USA

21 Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, Via Mariano Semmola, 80131, Naples, Italy

For all author emails, please log on.

Journal of Translational Medicine 2012, 10:83  doi:10.1186/1479-5876-10-83

Published: 2 May 2012


After more than 30 years, landmark progress has been made in the treatment of cancer, and melanoma in particular, with the success of new molecules such as ipilimumab, vemurafenib and active specific immunization.

After the first congress in December 2010, the second edition of “Melanoma Research: a bridge from Naples to the World” meeting, organized by Paolo A. Ascierto (INT, Naples, Italy), Francesco M. Marincola (NIH, Bethesda, USA), and Nicola Mozzillo (INT, Naples, Italy) took place in Naples, on 5–6 December 2011. We have identified four new topics of discussion: Innovative Approaches in Prevention, Diagnosis and Surgical Treatment, New Pathways and Targets in Melanoma: An Update about Immunotherapy, and Combination Strategies.

This international congress gathered more than 30 international faculty members and was focused on recent advances in melanoma molecular biology, immunology and therapy, and created an interactive atmosphere which stimulated discussion of new approaches and strategies in the field of melanoma.